Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

About this update from Lexeo Therapeutics, Inc.

Oral and poster presentations highlight progress across cardiac genetic medicine pipeline and optimized, Sf9-baculovirus AAV manufacturing platform NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that new data supporting its cardiac gene therapy programs and optimized AAV manufacturing approach will be presented at the 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 11-15, 2026 in Boston, MA. “We’re excited to return to ASGCT with a broad and compelling set of presentations that highlight the depth of Lexeo’s science and continued progress across our pipeline, from encouraging cardiac and neurologic data in Friedreich ataxia (FA) to a novel TNNI3 gene therapy program enabled by an innovative and clinically relevant porcine disease model, and an industry-leading, highly optimized AAV manufacturing platform,” said Narinder Bhalla, MD, Chief Medical Officer of Lexeo Therapeutics. “ASGCT provides an important opportunity to demonstrate the strength of our science to a broad industry audience, and we believe this work reflects our continued ability to advance differentiated programs with the potential to deliver meaningful impact for patients.” Lexeo Presentation Details: Oral PresentationTitle: A Gene Therapy Approach for the Treatment of TNNI3 Cardiomyopathy Presenter: Darla Tharp, PhD, University of MissouriDate/Time: Tuesday, May 12, 3:30 p.m. ETSession Title and Location: Preclinical Translational Large Animal Studies, MCEC Room 258ABC (Level 2)Presentation ID: 114 Oral PresentationTitle: Demonstrated Comparability Between Adherent HEK293 and Sf9 Baculovirus Suspension AAVrh.10 Clinical Manufacturing ProcessPresenter: Harris Shaikh, Lexeo Therapeutics Date/Time: Friday, May 15, 11:00 a.m. ETSession Title and Location: Analytics and Assay Development: Potency Evaluation, MCEC Room 257AB (Level 2)Presentation ID: 467 Poster PresentationTitle: Scale-Up and Manufacturing Comparability of an Sf RVN Baculovirus Production Process from 10 L to 200 L for AAVPresenter: Nene Kalu, PhD, Lexeo Therapeutics Date/Time: Thursday, May 14, 5:00 p.m. ETSession Title and Location: Poster Re...

View stock analysis, news, and events for Lexeo Therapeutics, Inc.